Tuesday, April 21, 2015

International Stem Cell Corp. (ISCO) Demonstrates Treatment of Parkinson’s Disease in Cell Transplantation

Today before the opening bell, International Stem Cell Corp., a biotechnology company developing novel stem cell based therapies and biomedical products, announced publication of results of two proof-of-concept studies that validate the safety and efficacy of the company’s readily expandable stem cell derived treatment of Parkinson’s disease in both non-human primate and rodent animal models.

“The publication of these data in the peer-reviewed and highly-respected journal, Cell Transplantation, brings to a conclusion the preclinical stage of our Parkinson’s disease program. The data clearly support the premise that parthenogenetic neural stem cells can be effective in treating the symptoms of Parkinson’s disease and, along with the previously reported safety data, forms the basis of our decision to move into the clinic,” stated Ruslan Semechkin, Ph.D., the Company’s Chief Scientific Officer. “We look forward to providing an update on the status of our regulatory submission to the Australian government in the near future.”

In addition to successfully treating animals with induced Parkinson’s disease symptoms by transplanting human parthenogenetic neural stem cells (hpNSC), the company observed there were no deformations, tumors or involuntary muscle movements (dyskinesia). The studies further show that transplants of human parthenogenetic neural stem cells led to improvement of dopamine levels and increased cytokine levels.

The article and abstract can be found at: http://www.ingentaconnect.com/content/cog/ct/2015/00000024/00000004/art00010

ISCO has built a comprehensive preclinical safety dataset from a series of GLP and non-GLP studies on hpNSC. According to today’s press release, the company has submitted a Clinical Trial Exemption (CTX) application to the Australian regulatory authorities and plans to begin the phase 1/2a clinical study within the next few months.

For more information on the company, visit www.internationalstemcell.com and www.companyblog.intlstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
           
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: